A new therapeutic target in T-ALL

In this press briefing session Etienne De Braekeleer of the Wellcome Sanger and Wellcome-MRC Cambridge Stem Cell Institutes, Cambridge, UK, discusses a new therapeutic target in T-cell Acute Lymphoblastic Leukemia (T-ALL), the gene NADK. Inhibition of NADK inhibited T-ALL cells from growing and prolonged the survival of mice with T-ALL, without causing noticeable side effects. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.